Humulin M3 Kwikpen (Insulin Human)

Humulin M3 Kwikpen is indicated for the long‑term control of hyperglycaemia in patients with diabetes who need a basal insulin component.

• Type 1 diabetes mellitus (insulin‑dependent) requiring basal insulin coverage to maintain fasting glucose levels.
• Type 2 diabetes mellitus when basal insulin is added to oral agents or other injectable therapies to improve overall glycaemic control.
• Combination therapy with rapid‑acting insulin analogues as part of a basal‑bolus regimen for flexible dosing throughout the day.
• Use in pediatric patients, including children and adolescents, as directed by a qualified healthcare professional.
• Consideration in pregnant or lactating women only after a thorough risk‑benefit assessment by the prescriber.

• Humulin M3 Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake, and inhibiting hepatic gluconeogenesis. The resulting effect lowers circulating glucose concentrations, providing basal insulin activity over several hours in patients.

Adverse reactions reported with Humulin M3 Kwikpen are generally related to its pharmacologic action or formulation.

Common

• Mild hypoglycaemia, presenting as shakiness, sweating, or dizziness, particularly when meals are missed, delayed, or carbohydrate intake is reduced.
• Local injection‑site reactions such as redness, swelling, itching or a transient lump at the puncture site.
• Lipodystrophy, including localized lipoatrophy (loss of subcutaneous fat) or lipohypertrophy (fat accumulation) at repeated injection sites.
• Gradual weight gain that may accompany improved glycaemic control and increased caloric storage.

Serious

• Severe hypoglycaemia with neuroglycopenic manifestations such as confusion, seizures, or loss of consciousness requiring assistance.
• Allergic responses ranging from urticaria and angio‑edema to rare anaphylactic shock.
• Persistent hyperglycaemia or ketoacidosis suggesting possible insulin resistance, dosing error, or inadequate basal coverage.

Before initiating Humulin M3 Kwikpen, healthcare providers should consider several precautionary measures to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycaemia unawareness or recurrent severe episodes.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Avoid use in patients with known hypersensitivity to human insulin or any pen components.
• Monitor blood glucose regularly to detect over‑ or under‑dosing.
• Counsel pregnant or lactating women about potential risks and benefits.
• Store the pen according to manufacturer instructions, protecting it from extreme temperatures.

Humulin M3 Kwikpen may interact with other medicines, affecting glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulin preparations without proper dose adjustment.
• Combination with sulfonylureas or meglitinides that increase hypoglycaemia risk.
• Use with beta‑blockers that may mask hypoglycaemia symptoms.

Use with caution

• Concomitant corticosteroids, which can raise blood glucose and require higher insulin doses.
• Thiazide diuretics or loop diuretics that may affect electrolyte balance and glucose control.
• MAO‑inhibitors or antidepressants that can alter carbohydrate metabolism.